Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PRAX

PRAX - Praxis Precision Medicines Inc Stock Price, Fair Value and News

$310.35-4.40 (-1.40%)
Market Closed

10/100

PRAX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

PRAX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$249.37

Target 3M

$280.54

Target 6M

$264.95

PRAX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PRAX Price Action

Last 7 days

-0.7%

Last 30 days

1.9%

Last 90 days

54.4%

Trailing 12 Months

311.8%

PRAX RSI Chart

PRAX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PRAX Valuation

Market Cap

7.8B

Price/Earnings (Trailing)

-28.42

Price/Sales (Trailing)

545.37

EV/EBITDA

-24.6

Price/Free Cashflow

-20.37

PRAX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$249.37

Target 3M

$280.54

Target 6M

$264.95

PRAX Fundamentals

PRAX Revenue

Revenue (TTM)

8.5M

PRAX Earnings

Earnings (TTM)

-273.0M

Earnings Growth (Yr)

-42.43%

Earnings Growth (Qtr)

-3.95%

PRAX Profitability

EBT Margin

-2148.26%

Return on Equity

-79.49%

Return on Assets

-68.88%

Free Cashflow Yield

-4.91%

PRAX Investor Care

Shares Dilution (1Y)

34.17%

Diluted EPS (TTM)

-12.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.2M1.8M1.6M8.6M
20231.3M1.7M2.1M2.4M
2022442.5K614.0K785.5K957.0K
2021205.5K00271.0K
2020166.5K00140.0K
2019000193.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Praxis Precision Medicines Inc

PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
 CEO
 WEBSITEhttps://praxismedicines.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES109

Praxis Precision Medicines Inc Frequently Asked Questions

PRAX is the stock ticker symbol of Praxis Precision Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Praxis Precision Medicines Inc is 7.76 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PRAX's fair value in chart for subscribers.

The fair value guage provides a quick view whether PRAX is over valued or under valued. Whether Praxis Precision Medicines Inc is cheap or expensive depends on the assumptions which impact Praxis Precision Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRAX.

As of Wed Jan 28 2026, PRAX's PE ratio (Price to Earnings) is -28.42 and Price to Sales (PS) ratio is 545.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRAX PE ratio will change depending on the future growth rate expectations of investors.